{
    "clinical_study": {
        "@rank": "89307", 
        "arm_group": [
            {
                "arm_group_label": "AMG 073", 
                "arm_group_type": "Experimental", 
                "description": "AMG 073"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This 6 month study will assess an investigational medication for patients on dialysis with\n      secondary hyperparathyroidism.  The study will look at the effects on parathyroid hormone,\n      calcium and phosphorus levels."
        }, 
        "brief_title": "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", 
        "completion_date": {
            "#text": "July 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Secondary Hyperparathyroidism", 
            "End Stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients must be receiving hemodialysis; have elevated parathyroid hormone levels; not be\n        pregnant or nursing; and not have had a heart attack in the last 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "380", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00042653", 
            "org_study_id": "20000188"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AMG 073", 
                "description": "30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally", 
                "intervention_name": "AMG 073", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Calcimimetic Agents"
        }, 
        "lastchanged_date": "May 6, 2013", 
        "link": [
            {
                "description": "AmgenTrials clinical trials website", 
                "url": "http://www.amgentrials.com"
            }, 
            {
                "description": "Notice regarding posted summaries of trial results", 
                "url": "http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf"
            }, 
            {
                "description": "To access clinical trial results information click on this link", 
                "url": "http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_38_AMG_073_20000188.pdf"
            }, 
            {
                "description": "FDA-approved Drug Labeling", 
                "url": "http://www.sensipar.com/"
            }
        ], 
        "number_of_arms": "2", 
        "official_title": "A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.", 
            "safety_issue": "No", 
            "time_frame": "Efficacy Assessment phase - final 10 weeks of study"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042653"
        }, 
        "responsible_party": {
            "name_title": "Global Development Leader", 
            "organization": "Amgen Inc."
        }, 
        "results_reference": {
            "PMID": "15689407", 
            "citation": "Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005 Mar;16(3):800-7. Epub 2005 Feb 2."
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate the efficacy of AMG 073 compared with placebo by determining:  the proportion of subjects with a reduction from baseline in mean iPTH of >= 30% during the efficacy assessment phase", 
                "safety_issue": "No", 
                "time_frame": "Efficacy Assessment phase - final 10 weeks of study"
            }, 
            {
                "measure": "To evaluate the efficacy of AMG 073 compared with placebo by determining:  percentage change from baseline in iPTH during the efficacy assessment phase", 
                "safety_issue": "No", 
                "time_frame": "Efficacy Assessment phase - final 10 weeks of study"
            }, 
            {
                "measure": "To evaluate the safety of AMG 073 compared with placebo", 
                "safety_issue": "Yes", 
                "time_frame": "Entire study - 26 weeks"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {}
}